{"entity":{"id":"trevarx-biomedical","kind":"company","name":"Trevarx Biomedical","aka":["Trevarx Biomedical, Inc.","Trevarx"],"tldr":"Trevarx Biomedical is a Philadelphia company attaching a radioactive atom to a PARP inhibitor so that radiation is released right at a tumour cell's DNA. Its first drug, AlphaPARP, is being prepared for ovarian cancer.","summary":"Trevarx Biomedical, Inc. is building a DNA-directed alpha radiopharmaceutical platform. Its first therapeutic, AlphaPARP, is astatine-211 attached to a PARP inhibitor backbone (Parthanatine), designed to bind activated PARP1 at sites of tumour DNA damage so that alpha energy is deposited next to the DNA; the company says it is seeking a USD 35 million Series A. A 2026 National Cancer Institute SBIR award funds preparation for a phase 1 IND of the agent in ovarian cancer, and the award abstract describes a companion PET imaging agent that binds the same target for patient selection.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.trevarx.com/"},{"label":"NIH RePORTER: award 1R44CA310342-01A1","url":"https://reporter.nih.gov/project-details/11408032"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["radiopharma"],"technologies":["astatine-211-alpha-therapy","targeted-alpha-therapy"],"targets":["parp"],"drugs":["alphaparp"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website and the NIH RePORTER record read on 4 November 2026. Founding year not stated on the website."],"hq":"Philadelphia, PA","country":"US","companyType":"radiopharma","website":"https://www.trevarx.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1174824,"source":"https://reporter.nih.gov/project-details/11408032","note":"NCI SBIR (R44) award 1R44CA310342-01A1: Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer"}]},"route":"/companies/trevarx-biomedical/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"alphaparp","kind":"drug","name":"AlphaPARP","route":"/drugs/alphaparp/"}]}}